Important: This is educational content, not prescribing advice. Use is off-label and must comply with your jurisdiction's regulations and standards of care.

1. Clinical Overview of GHK-Cu

Molecule: Glycyl-L-histidyl-L-lysine-copper

Physiology: Endogenous copper-binding tripeptide present in plasma, saliva, and urine. Serum levels decline with age (approx. 200 ng/mL at ~20 years → ~80 ng/mL at ~60 years).

Key Documented Actions

Stimulates collagen I & III, elastin, and glycosaminoglycan synthesis
Modulates MMPs/TIMPs, facilitating removal of damaged matrix and deposition of new collagen
Supports wound healing, angiogenesis, and re-epithelialization
Exhibits anti-inflammatory and antioxidant properties
Influences gene expression patterns associated with tissue repair and anti-aging

Clinical Domains of Interest

Photoaging and dermal atrophy
Post-procedure recovery (microneedling, RF, laser)
Scar modulation
Hair density and quality support
General regenerative support (in combination with other peptides)

2. Oral GHK-Cu Protocol — Peptide Protocol Portal RECOVER™

2.1 Formulation Summary (RECOVER™)

Each RECOVER™ capsule contains:
BPC-157 — 500 mcg · GHK-Cu — 2 mg · Carnosine — 500 mg

Delivery Technology

Enteric-coated capsule (pH-dependent dissolution, typically ≥5.5)
Internal multi-phase micro-pellets:
- Immediate-release Carnosine (redox / anti-glycation support)
- Sustained-release GHK-Cu (matrix remodeling)
- Delayed-release BPC-157 (angiogenesis / tissue repair / GI support)

This design targets sequential activation of antioxidant, extracellular matrix, and regenerative pathways.

2.2 Standard Oral Protocol (Physician-Guided)

Dose: 1 capsule in the morning on an empty stomach with a full glass of water
Cycle: 5 days on, 2 days off to reduce theoretical receptor / pathway desensitization
Course Length: 60-capsule bottle ≈ 3-month supply at 5-on/2-off schedule

Typical Clinical Scenarios

Adjunct for dermal anti-aging and photoaging protocols
Systemic support during courses of microneedling, RF, or laser
Soft-tissue recovery and inflammatory modulation (especially when BPC-157's GI and tendon effects are desirable)

2.3 Decision Tree 1 — When to Use Oral RECOVER™

1. Is the patient undergoing (or planning) tissue-stress or remodeling interventions?

Examples: microneedling series, RF/laser resurfacing, surgery, intensive physical training.

If YES → go to Step 2 · If NO → consider RECOVER™ only if chronic tissue damage or systemic inflammation is present.

2. Is there a need for both systemic regenerative support and local dermal/aesthetic therapy?

YES → RECOMMEND RECOVER™ + appropriate topical/procedural protocol.

NO → topical/local approaches may suffice.

3. Any contraindications or concerns?

Copper metabolism disorders (e.g., Wilson disease), severe hepatic impairment, complex polypharmacy affecting copper status.

If any present → consider avoiding or using with heightened caution and monitoring.

4. Patient Commitment & Compliance:

If YES → integrate RECOVER™ as systemic backbone. · If NO → focus on procedural + topical only.

3. Topical GHK-Cu Protocols

3.1 Stand-Alone Topical Regimen

Indications

Fine lines, texture, mild–moderate photoaging
Early laxity and dermal thinning
Support for general skin quality and tone

Typical Clinical Implementation

Vehicle: Serum or light cream, face/neck focus
Concentration: Commonly 0.1–0.5% GHK-Cu for facial applications; higher concentrations for thicker skin or localized areas
Frequency: Once or twice daily on clean skin
Sequence: After cleansing; before heavier moisturizers or occlusives
Course: 8–12 weeks minimum before formal evaluation of dermal remodeling

3.2 Microneedling + GHK-Cu Protocol

Use case: Optimize dermal penetration and collagen stimulation in acne scars, fine lines, and global rejuvenation.

Pre-conditioning (optional but beneficial): Topical GHK-Cu once daily 2–4 weeks prior to the microneedling series for matrix priming.
Peri-procedural use: Perform microneedling to clinically appropriate depth and coverage. Immediately post-treatment, apply a sterile GHK-Cu solution or serum: thin, even layer; allow to absorb without aggressive manipulation. Follow clinic's established post-needling care.
Post-procedure home care: Once barrier recovery is adequate (24–72 hours depending on depth/device), resume or initiate daily topical GHK-Cu as tolerated. Continue through the series (e.g., every 4 weeks for 3–6 sessions).

3.3 Laser/RF + GHK-Cu Protocol

Pre-treatment: Start topical GHK-Cu once daily 2–4 weeks before a series of non-ablative or fractional RF/laser treatments.
Milder non-ablative devices: Introduce GHK-Cu after initial acute healing phase (often 24–72 hours post-treatment).
Ablative/fractional procedures: Delay reintroduction until re-epithelialization and barrier recovery are firmly established.
Maintenance: Continue once-daily GHK-Cu for 4–12 weeks after completing the treatment series.

3.4 GHK-Cu + PRiVIVE™ Integration

Concept: PRiVIVE™ delivers autologous platelet-derived growth factors, cytokines, and extracellular vesicles from the patient, while GHK-Cu adds matrix remodeling and gene-expression modulation.

Options

Sequential Application (preferred): In-office: apply PRiVIVE™ per IFU immediately after microneedling/RF/laser. Once absorbed, layer a GHK-Cu topical, or reserve GHK-Cu for home care.
Same-session admixture (advanced clinics): Perform under sterile technique. Use promptly; document compounding step in chart and consent.
Home Maintenance: PRiVIVE™ used as directed post-procedure (short course). GHK-Cu serum or cream for long-term maintenance (8–12 weeks or ongoing).

Decision Tree 2 — Topical & Procedural Strategy

1. Is the primary indication aesthetic (skin quality, scars, photoaging)?

YES → go to Step 2 · NO → consider topical GHK-Cu only as adjunct or use oral RECOVER™ when systemic support is needed.

2. Is the patient undergoing a device-based treatment (microneedling, RF, laser)?

YES → Precondition with topical GHK-Cu; use GHK-Cu post-procedure; consider PRiVIVE™ + GHK-Cu for higher-value procedures.

NO → Stand-alone topical regimen ± oral RECOVER™ for conservative rejuvenation.

3. Is the patient able to adhere to multi-step home regimens?

YES → combine oral RECOVER™, topical GHK-Cu, and scheduled procedures.

NO → prioritize one or two key interventions (e.g., procedures + simple topical plan).

4. Injectable GHK-Cu — 100 mg Lyophilized Vial

Regulatory & Safety Reminder: Injectable GHK-Cu is off-label and typically designated for research use. Protocols must comply with local law, licensing requirements, and institutional or board policies. This section provides only high-level considerations.

4.1 Product & Reconstitution Considerations

Vial Content: 100 mg lyophilized GHK-Cu · Diluent: Bacteriostatic saline or BAC water per clinic SOP · Aseptic technique is mandatory.

Example reconstitution math:
Add 10 mL diluent → 10 mg/mL (1 mg = 0.1 mL)
Add 20 mL diluent → 5 mg/mL (1 mg = 0.2 mL)

4.2 Indication Context (Research)

Local intradermal treatment for photoaged skin or scars
Injection into/scalp grid patterns for hair density work
Perilesional injections for wound/scar modulation

Decision Tree 3 — Should Injectable GHK-Cu Be Considered?

1. Is topical and/or oral therapy sufficient?

YES → prioritize non-invasive approaches; injectable use generally not required.

NO → go to Step 2.

2. Does the clinician have specific training with mesotherapy / intradermal injection?

NO → avoid injectable GHK-Cu; consider referral or topical/oral.

YES → go to Step 3.

3. Patient risk assessment: Copper metabolism disorder? Significant hepatic disease? High medication burden affecting metal handling?

If YES to any → relatively contraindicated; proceed only with extreme caution or avoid.

If NO → go to Step 4.

4. Is the indication clearly localized and refractory to non-invasive treatment?

YES → injectable route may be considered in a controlled, documented research/off-label framework with robust informed consent.

NO → continue or optimize non-invasive protocols.

5. Safety, Contraindications & Monitoring

5.1 Topical

Generally well tolerated; common minor effects: local redness, tingling, mild irritation.
Caution in active dermatitis or broken skin, and post-ablative periods until barrier recovery.

5.2 Oral (RECOVER™ Capsule)

GHK-Cu is an endogenous peptide; systemic exposure at these doses is modest. Consider additional caution in:

Wilson disease or other copper storage disorders
Advanced liver disease
Patients on complex mineral/metal chelation regimens

Monitoring (as clinically warranted): Subjective response (skin, energy, recovery), GI tolerance, basic labs in high-risk patients (LFTs, CBC, copper, ceruloplasmin).

5.3 Injectable

Injection-site pain, nodules, or inflammation
Local infection (if aseptic technique is inadequate)
Systemic symptoms with higher or cumulative dosing
Potential copper accumulation with aggressive or prolonged protocols

Best practices: Conservative dosing and limited courses, specific informed consent, document indication/dose/route/response, avoid co-administration of high oral copper supplementation unless carefully monitored.

6. Putting It All Together — Integrated GHK-Cu Protocol Archetypes

Archetype A — Aesthetic Skin Rejuvenation (Non-Surgical)

Systemic Backbone:

RECOVER™ 1 capsule AM, 5-on/2-off for 12 weeks

Local Therapy:

GHK-Cu serum once daily to face/neck for 12 weeks

Procedural Course (optional):

Microneedling or RF every 4–6 weeks × 3–4 sessions
PRiVIVE™ + GHK-Cu peri-procedurally in-office

Archetype B — High-Output Recovery / Mixed Aesthetic and Orthopedic

Systemic:

RECOVER™ (as above)
Consider REVIVE™ AM for mitochondrial/metabolic support

Local:

GHK-Cu topically to both aesthetic and musculoskeletal target areas (e.g., post-PRP injections or soft-tissue work)

Archetype C — Neurocognitive + Aesthetic Support

Systemic:

RECOVER™ AM
REBALANCE™ 2 caps PM (5-on/2-off)

Local:

Facial topical GHK-Cu regimen + procedural series as appropriate

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

GHK-Cu (Copper Tripeptide-1), BPC-157, SLU-PP-332, 5-Amino-1MQ, and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — GHK-Cu (Copper Tripeptide-1) Clinical Reference Guide

1. Pickart, L. The human tripeptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 19(8), 969–988 (2008).

2. Pickart, L., Margolina, A. GHK peptide as a natural modulator of gene expression: Implications for wound healing and tissue regeneration. BioMed Research International, 2015, 648108 (2015).

3. Pickart, L., Thaler, M. Evidence that GHK-Cu regenerates skin fibroblasts and extracellular matrix. International Journal of Cosmetic Science, 9(4), 167–175 (1987).

4. Maquart, F. X., Pickart, L., Laurent, M., et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex GHK-Cu. FEBS Letters, 238(2), 343–346 (1988).

5. Simeon, A., Wegrowski, Y., Bontemps, Y., Maquart, F. X. GHK-Cu increases the synthesis of decorin and angiogenesis regulators. Journal of Cellular Physiology, 177(1), 1–9 (1998).

6. Finkey, M. B., et al. Copper peptide–induced wound contraction and accelerated healing in animal models. Wounds, 13(1), 14–22 (2001).

7. Tan, Y., et al. GHK-Cu and anti-inflammatory pathways: Modulation of NF-κB and cytokines. Molecular and Cellular Biochemistry, 360, 19–27 (2012).

8. Canapp, S. O., et al. GHK-Cu in tendon and ligament healing: Implications for regenerative orthopedics. Veterinary Surgery, 39(7), 936–943 (2010).

9. Pickart, L., Vasquez-Sawyer, J. GHK-Cu and antioxidant pathways: Protection against reactive oxygen species. Free Radical Biology & Medicine, 26(3–4), 234–241 (1999).

10. Pollard, H. B., et al. GHK-Cu as a regulator of gene expression: Upregulation of 4,000+ beneficial genes. Physiological Genomics, 44(24), 1198–1206 (2012).

11. Al Tuwaijri, A. A., et al. Topical GHK-Cu improves photoaged skin and reduces wrinkles. Dermatologic Surgery, 22(4), 347–351 (1996).

12. Leyden, J., et al. A randomized clinical trial of copper tripeptide vs vitamin C vs retinoic acid. Journal of Cosmetic Dermatology, 1(1), 20–28 (2002).

13. Fitzgerald, K. M., et al. GHK-Cu promotes angiogenesis and improves microcirculation. Microvascular Research, 56(2), 174–186 (1998).

14. Ahmed, M. I., et al. GHK-Cu improves hair follicle growth and enlarges follicular bulb size. Journal of Dermatological Treatment, 24(3), 171–178 (2013).

15. Pickart, L., Margolina, A. The effect of the copper peptide GHK-Cu on nerve outgrowth and neuroprotection. Brain Research Bulletin, 158, 21–28 (2020).

16. Godin, M. S., et al. GHK-Cu enhances wound healing and decreases scar tissue formation. Aesthetic Surgery Journal, 14(2), 94–104 (1994).

17. Siméon, A., et al. GHK-Cu increases metalloproteinase-2 (MMP-2) activity and accelerates ECM turnover. Biochemical Pharmacology, 59(10), 1248–1254 (2000).

18. Harsha, C., et al. Copper peptides and skin-barrier repair: Anti-inflammatory and antioxidant synergy. International Journal of Molecular Sciences, 20(4), 908 (2019).

19. Arul, V., et al. GHK-Cu accelerates healing in diabetic and ischemic wound models. Journal of Surgical Research, 178(1), 79–87 (2012).

20. Martinez, M. A., et al. Copper-modulating peptides in regenerative medicine: Clinical implications for skin, tendon, and organ repair. Frontiers in Medicine, 7, 178 (2020).

21. Pickart, L. GHK-Cu: Multifunctional regulator of growth, repair, and gene expression. International Journal of Cosmetic Science, 37(S2), 15–20 (2015).

22. Leachman, S. A., et al. GHK-Cu enhances integrin signaling and stem cell activation in injured tissue. Stem Cells and Development, 12(4), 423–431 (2003).

GHK-Cu (Blue Copper Peptide)